Bromocriptine

Ergot Derivative — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Bromocriptine is an ofp drug in the Ergot Derivative class catalogued in DrugCentral. It was first approved by the FDA in 1978. DrugCentral lists 35 molecular targets, including DRD2, ADRA1B and Adra1b. Recorded indications include Acromegaly, Hyperprolactinemia, Parkinson's disease and Postencephalitic parkinsonism.

• Approval status: ofp (first approved 1978 by the FDA).
• Drug class: Ergot Derivative.
• Molecular targets: DRD2, ADRA1B, Adra1b and ADRA1D (35 listed in DrugCentral).
• Indications: Acromegaly, Hyperprolactinemia, Parkinson's disease, Postencephalitic parkinsonism and Type 2 Diabetes Mellitus Treatment Adjunct.
• ATC code: G02CB01 (Prolactine inhibitors).
• Molecular formula: C32H40BrN5O5; molecular weight 654.61 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Acromegaly
• Hyperprolactinemia
• Parkinson's disease
• Postencephalitic parkinsonism
• Type 2 Diabetes Mellitus Treatment Adjunct

Off-label uses (1)

• Neuroleptic malignant syndrome

Contraindications (11)

• Breastfeeding (mother)
• Cerebrovascular accident
• Disease of liver
• Disorder of coronary artery
• Eclampsia in pregnancy
• Hypertensive disorder
• Hypertensive urgency
• Mild pre-eclampsia
• Pregnancy-induced hypertension
• Psychiatric Disturbance
• Severe pre-eclampsia

Mechanism & targets

• Established pharmacologic class: Ergot Derivative

Molecular targets (35)

Target	Gene	Action	Activity
D(2) dopamine receptor	DRD2	agonist	Ki 9.70
Alpha-1B adrenergic receptor	ADRA1B	unknown	Ki 8.86
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 8.71
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 8.55
D(2) dopamine receptor	Drd2	unknown	Kd 8.40
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 8.38
5-hydroxytryptamine receptor 1A	Htr1a	unknown	IC50 8.25
Alpha-1A adrenergic receptor	Adra1a	unknown	IC50 8.16
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 8.00
5-hydroxytryptamine receptor 7	Htr7	agonist	Ki 8.00
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 8.00
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 7.90
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 7.60
Dopamine receptor	Drd1|Drd3|Drd5|Drd4|Drd2	unknown	IC50 7.55
D(3) dopamine receptor	DRD3	agonist	Ki 7.50
5-hydroxytryptamine receptor 6	HTR6	agonist	Ki 7.50
5-hydroxytryptamine receptor 6	Htr6	agonist	Ki 7.50
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 7.50
5-hydroxytryptamine receptor 1B	Htr1b	unknown	Ki 7.33
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 7.30

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-06-28	FDA	—	US PHARMS HOLDINGS I

ATC classification

ATC code	Therapeutic hierarchy
G02CB01	GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Prolactine inhibitors
N04BC01	NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Dopamine agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Neuroleptic malignant syndrome	217.6
Blood prolactin increased	93.3
Gambling disorder	89.4
Muscle rigidity	74.4
Visual pathway disorder	66.3
Hypersexuality	62.4
Serotonin syndrome	58.7
Exposure during pregnancy	57.5
Premature baby	55.3
Mediastinal fibrosis	50.1
Maternal exposure during pregnancy	47.7
Stress cardiomyopathy	47.6

Chemical structure

• Molecular formula: C₃₂H₄₀BrN₅O₅
• Molecular weight: 654.61 g/mol
• CAS number: —
• InChIKey: OZVBMTJYIDMWIL-AYFBDAFISA-N
• PubChem CID: 31101

CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bromocriptine used for?

DrugCentral lists the following indications for Bromocriptine: Acromegaly, Hyperprolactinemia, Parkinson's disease, Postencephalitic parkinsonism and Type 2 Diabetes Mellitus Treatment Adjunct.

How does Bromocriptine work?

Its molecular targets in DrugCentral include DRD2 (agonist), ADRA1B, Adra1b and ADRA1D.

When was Bromocriptine first approved?

Bromocriptine was first approved by the FDA in 1978.

What drug class does Bromocriptine belong to?

Bromocriptine is in the Ergot Derivative class.

What is the chemical formula of Bromocriptine?

Bromocriptine has the molecular formula C32H40BrN5O5 and a molecular weight of 654.61 g/mol.

Sources

• DrugCentral drug card 403 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200503 — compound record and bioactivity
• PubChem CID 31101 — chemical identifiers
• DrugBank DB01200 — drug record
• FDA UNII 3A64E3G5ZO — substance identity
• DailyMed: FDA labels for Bromocriptine — current prescribing information (label search)
• UniProt P14416 (DRD2) — target protein
• UniProt P35368 (ADRA1B) — target protein
• UniProt P25100 (ADRA1D) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P28221 (HTR1D) — target protein
• UniProt P08913 (ADRA2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.